22 TWENTYFOURSEVENBIOPHARMA Issue 3 / October 2025 NEWS Ncardia, a leader in stem cell– based solutions for drug discovery and safety assessment, today announced the launch of Ncyte® NHP-C vCardiomyocytes, the first commercially available ventricular-like cardiomyocytes derived from induced pluripotent stem cells (iPSCs) of cynomolgus monkeys. New Ncyte® NHP-C vCardiomyocytes provide a scalable, ethical and translational tool for cross-species cardiac studies. The innovation addresses a growing need for physiologically relevant, non-human primate (NHP) in vitro models that reduce reliance on live animals in preclinical research. With the launch of Ncyte® NHP-C vCardiomyocytes, Ncardia empowers the scientific community to conduct crossspecies mechanistic studies, improve predictive modeling of cardiotoxicity and lower risk in drug development — all while advancing more ethical preclinical practices in alignment with the FDA recent animal testing guidance. Ncyte® NHP-C vCardiomyocytes offer a high-purity, functional alternative that closely mimics human cardiac electrophysiology and pharmacology. The cells enable more predictive, scalable and ethical safety screening across species, supporting pharmaceutical and biotech companies in advancing safer therapies. “As the only iPSC-derived NHP ventricular cardiomyocytes on the market, Ncyte® NHP-C vCardiomyocytes set a new standard for translational cardiovascular research,” said Jeroen de Groot, divisional chief executive of Ncardia. “They give researchers the ability to perform direct crossspecies comparisons in vitro, improve cardiotoxicity risk assessment and meet the FDA’s evolving expectations around reducing the use of live nonhuman primates in safety testing.” Ncardia launches first-of-its-Kind iPSC-derived non-human primate cardiomyocytes to advance cardiac safety research At this year’s CPHI Europe in Frankfurt (28–30 October), BENEO will showcase the latest advancements in granulation with its pharmaceutical-grade isomalt excipient: galenIQ™. Visitors are invited to connect with the BENEO team at Stand 8.0L70, where experts will present new data, application samples, and formulation insights for oral dosage forms. As continuous manufacturing becomes increasingly prominent in the pharmaceutical industry, BENEO’s galenIQ™ offers a compelling binder solution. Its unique performance profile includes fast preparation, robust granule formation, excellent flowability, and rapid dissolution – key factors for success in both twin screw and high-shear granulation. Designed to meet the dual requirements of efficient manufacturing and enhanced patient compliance, galenIQ™ combines technical performance with sensory appeal. Thanks to its pleasant, sweet taste and plant-based origin, it supports the development of more palatable and patient-friendly dosage forms. Produced from CPHI 2025: BENEO to present galenIQ™ as the granulation binder of choice
RkJQdWJsaXNoZXIy MjY2OTA4MA==